| Literature DB >> 31477126 |
Mohamed Abdelgied1,2,3, Ahmed M El-Gazzar1,2,4, William T Alexander1, Takamasa Numano1, Masaaki Iigou1, Aya Naiki-Ito2, Hiroshi Takase5, Akihiko Hirose6, Yuhji Taquahashi7, Jun Kanno8, Mona Abdelhamid9,10, Khaled Abbas Abdou3, Satoru Takahashi2, David B Alexander11, Hiroyuki Tsuda12.
Abstract
BACKGROUND: Potassium octatitanate fibers (K2O•8TiO2, POT fibers) are used as an asbestos substitute. Their physical characteristics suggest that respirable POT fibers are likely to be carcinogenic in the lung and pleura. However, previous 2-year inhalation studies reported that respired POT fibers had little or no carcinogenic potential. In the present study ten-week old male F344 rats were left untreated or were administered vehicle, 0.25 or 0.5 mg rutile-type nano TiO2 (r-nTiO2), 0.25 or 0.5 mg POT fibers, or 0.5 mg MWCNT-7 by intra-tracheal intra-pulmonary spraying (TIPS), and then observed for 2 years.Entities:
Keywords: Intra-tracheal intra-pulmonary spraying; Lung carcinoma; MWCNT-7; Malignant mesothelioma; Potassium octatitanate fibers; TIPS
Mesh:
Substances:
Year: 2019 PMID: 31477126 PMCID: PMC6720102 DOI: 10.1186/s12989-019-0316-2
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Fig. 1Gross appearance of a malignant mesothelioma from a rat in the 0.25 mg POT fiber treated group (died at 98 week) showing small nodules on the surface of the pericardium (black arrows) and red pleural effusion in the thoracic cavity. In this animal, the mediastinal area of the lung was adherent to the diaphragm (green arrow)
Proliferative lesions in the lung and pleura
| Group | Untreated | Vehicle | r-nTiO2 0.25 mg | r-nTiO2 0.50 mg | POT 0.25 mg | POT 0.50 mg | MWCNT-7 0.50 mg |
|---|---|---|---|---|---|---|---|
| Number of animals | 19 | 19 | 20 | 19 | 17 | 16 | 14 |
| Bronchiolo-alveolar hyperplasia | 2 | 2 | 0 | 2 | 7 | 10** | 14a,*** |
| Bronchiolo-alveolar adenoma | 0 | 1 | 2 | 0 | 1 | 0 | 1 |
| Bronchiolo-alveolar adenocarcinoma | 3 | 0 | 0 | 2 | 0 | 2 | 5 |
| Squamous cell carcinoma | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Mesothelial cell hyperplasia | 0 | 0 | 0 | 0 | 4* | 7** | 10*** |
| Visceral mesothelioma | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Parietal mesothelioma | 0 | 0 | 0 | 0 | 2 | 1 | 2 |
| Carcinoma + Mesothelioma | 3 | 0 | 0 | 2 | 4 | 2b | 6b |
aThree animals also had bronchiolar hyperplasia
bOne animal had bronchiolo-alveolar carcinoma and parietal mesothelioma
*,**,***Different from both the Untreated and the Vehicle Control at p < 0.05, p < 0.01, p < 0.001, respectively
Fig. 2Pulmonary alveolar cell hyperplasia in rats in the 0.50 mg POT (a, b) and 0.50 mg MWCNT-7 (c, d) treated groups. Infiltration of alveolar macrophages phagocytizing POT fibers and MWCNT-7 (black arrows), thickening and fibrosis of the alveolar wall (blue arrows), and hyperplasia of alveolar epithelium (green arrows) can be seen. Insert, polarized light microscope images
Fig. 3Pulmonary bronchiolo-alveolar cell carcinomas from rats in the untreated (a), 0.50 mg r-nTiO2 (b), 0.50 mg POT (c), and 0.50 mg MWCNT-7 (d) treated groups. Proliferative fibrous connective tissue can be seen in the carcinomas from the rats in the POT and MWCNT-7 treated groups (asterisks in panel c and d inserts), but not in the carcinomas from the rats in the untreated and r-nTiO2 treated groups
Fig. 4Squamous cell carcinoma from a rat in the 0.25 mg POT treated group
Fig. 5Pleural hyperplasia in rats in the POT fiber (a, b, c) and MWCNT-7 (d, e, f) treated groups. Visceral pleura (a, d), diaphragmatic region of the parietal pleura (b, e), and costal region of the parietal pleura (c, f)
Fig. 6Malignant pleural mesotheliomas. A sarcomatoid type mesothelioma of the costal region of the parietal pleura in a rat from the 0.50 mg POT fiber treated group (a, b). An epitheliod type mesothelioma of the diaphragmatic region of the parietal pleura invading into the pleural cavity and the visceral pleura in a rat from the 0.25 mg POT treated group (c, d). An epitheliod type mesothelioma of the costal region of the parietal pleura in a rat from the MWCNT-7 group (e, f)
Size of test materials in suspension before administration and materials collected from the lung, mediastinal lymph node, and pleural cavity cell pellet at 2 years
| r-nTiO2 | POT | MWCNT-7 | ||
|---|---|---|---|---|
| Suspension | Length (μm) | 0.050 ± 0.008 | 6.06 ± 1.53 | 5.31 ± 3.81 |
| Width (nm) | 14.35 ± 4.63 | 305.00 ± 69.00 | 75.65 ± 20.54 | |
| Lung | Length (μm) | ND | 8.13 ± 6.90 | 4.48 ± 2.54 |
| Width (nm) | ND | 329.90 ± 173.22 | 90.18 ± 31.84 | |
| Mediastinal lymph node | Length (μm) | ND | 4.95 ± 2.57 | 5.83 ± 1.54 |
| Width (nm) | ND | 297.75 ± 104.85 | 39.54 ± 5.90 | |
| Pleural cavity | Length (μm) | ND | 8.93 ± 1.38 | 10.38 ± 2.76 |
| Width (nm) | ND | 375.73 ± 59.73 | 42.50 ± 17.02 |
ND Not Detected
Fig. 7SEM of POT fibers (a, b, c) and MWCNT-7 (d, e, f) in digested lung (a, d) and mediastinal lymph nodes (b, e), and in the pleural cavity lavage cell pellet (c, f)